» Articles » PMID: 32469963

Amyloid β Induces Interneuron-specific Changes in the Hippocampus of APPNL-F Mice

Overview
Journal PLoS One
Date 2020 May 30
PMID 32469963
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and amyloid-beta (Aβ) depositions generated by the proteolysis of amyloid precursor protein (APP) in the brain. In APPNL-F mice, APP gene was humanized and contains two familial AD mutations, and APP-unlike other mouse models of AD-is driven by the endogenous mouse APP promoter. Similar to people without apparent cognitive dysfunction but with heavy Aβ plaque load, we found no significant decline in the working memory of adult APPNL-F mice, but these mice showed decline in the expression of normal anxiety. Using immunohistochemistry and 3D block-face scanning electron microscopy, we found no changes in GABAA receptor positivity and size of somatic and dendritic synapses of hippocampal interneurons. We did not find alterations in the level of expression of perineuronal nets around parvalbumin (PV) interneurons or in the density of PV- or somatostatin-positive hippocampal interneurons. However, in contrast to other investigated cell types, PV interneuron axons were occasionally mildly dystrophic around Aβ plaques, and the synapses of PV-positive axon initial segment (AIS)-targeting interneurons were significantly enlarged. Our results suggest that PV interneurons are highly resistant to amyloidosis in APPNL-F mice and amyloid-induced increase in hippocampal pyramidal cell excitability may be compensated by PV-positive AIS-targeting cells. Mechanisms that make PV neurons more resilient could therefore be exploited in the treatment of AD for mitigating Aβ-related inflammatory effects on neurons.

Citing Articles

Quantification and correlation of amyloid-β plaque load, glial activation, GABAergic interneuron numbers, and cognitive decline in the young TgF344-AD rat model of Alzheimer's disease.

Futacsi A, Rusznak K, Szarka G, Volgyi B, Wiborg O, Czeh B Front Aging Neurosci. 2025; 17:1542229.

PMID: 40013092 PMC: 11860898. DOI: 10.3389/fnagi.2025.1542229.


The Bidirectional Relationship Between Epilepsy and Alzheimer's Disease.

Stewart D, Johnson E Curr Neurol Neurosci Rep. 2025; 25(1):18.

PMID: 39921833 DOI: 10.1007/s11910-025-01404-y.


Specific and Plastic: Chandelier Cell-to-Axon Initial Segment Connections in Shaping Functional Cortical Network.

Qi Y, Zhao R, Tian J, Lu J, He M, Tai Y Neurosci Bull. 2024; 40(11):1774-1788.

PMID: 39080101 PMC: 11607270. DOI: 10.1007/s12264-024-01266-3.


An Expanded Narrative Review of Neurotransmitters on Alzheimer's Disease: The Role of Therapeutic Interventions on Neurotransmission.

Akyuz E, Arulsamy A, Aslan F, Sarisozen B, Guney B, Hekimoglu A Mol Neurobiol. 2024; 62(2):1631-1674.

PMID: 39012443 PMC: 11772559. DOI: 10.1007/s12035-024-04333-y.


Native-state proteomics of Parvalbumin interneurons identifies unique molecular signatures and vulnerabilities to early Alzheimer's pathology.

Kumar P, Goettemoeller A, Espinosa-Garcia C, Tobin B, Tfaily A, Nelson R Nat Commun. 2024; 15(1):2823.

PMID: 38561349 PMC: 10985119. DOI: 10.1038/s41467-024-47028-7.


References
1.
Ramos B, Baglietto-Vargas D, Del Rio J, Moreno-Gonzalez I, Santa-Maria C, Jimenez S . Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol Aging. 2005; 27(11):1658-72. DOI: 10.1016/j.neurobiolaging.2005.09.022. View

2.
Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I . Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. Acta Neuropathol. 2011; 123(1):53-70. PMC: 3249205. DOI: 10.1007/s00401-011-0896-x. View

3.
Masuda A, Kobayashi Y, Kogo N, Saito T, Saido T, Itohara S . Cognitive deficits in single App knock-in mouse models. Neurobiol Learn Mem. 2016; 135:73-82. DOI: 10.1016/j.nlm.2016.07.001. View

4.
Morrison J, Rogers J, Scherr S, Benoit R, Bloom F . Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients. Nature. 1985; 314(6006):90-2. DOI: 10.1038/314090a0. View

5.
Janus C, Pearson J, McLaurin J, Mathews P, Jiang Y, Schmidt S . A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2001; 408(6815):979-82. DOI: 10.1038/35050110. View